Trouble for Big Pharma over the last few years:

The Alliance for Human Research

Protection prepared ,

Trouble for Big Pharma over the last few years:

2001: "TAP-Astra Zeneca Pay Over a Billion Dollar in Fines" -- re: criminal

marketing of Lupron.

2002: Pfizer paid $49 million to settle state and federal Medicaid fraud charges

involving Lipitor.

2002: Schering-..Plough signed a FDA consent decree and paid a $500 million fine --

the biggest in FDA history -- for violating manufacturing standards.

2004: Schering-..Plough paid $345 million to resolve criminal and civil liabilities

for illegal marketing of Calritin.

2004: Pfizer admitted criminal marketing of Neurontin, agreeing to pay $420

million.

2003: Bayer pled guilty to violating the federal Prescription Drug Marketing Act,

paying $257 million including a criminal fine for its marketing of Cipro.

2004: Merck withdrew its lethal painkiller, Vioxx. Estimates are that it would cost

the company $50 billion.

2004: The IRS served Merck with a "preliminary notice of deficiency" that could

lead to $2.04 billion payment for back taxes.

2003: GlaxoSmithKline.. shareholders questioned GSK CEO, Jean-Pierre Garnier, about

his pay package to which he responded: "I am not Mother Teresa." GlaxoSmithKline..

also ran afoul of the IRS -- it is facing a demand for $7.8 billion in backdated

taxes and interest.

2003: GSK signed a corporate integrity agreement and paid $88 million in a civil

fine for overcharging Medicaid for the antidepressant,.. Paxil and nasal-allergy

spray, Flonase.

2004: New York State Attorney General slapped GSK with fraudulent marketing of

Paxil -- the company settled and posted its previously concealed pediatric clinical

trial data.

2005: the Justice Department announced that GSK had paid "over $150 million to

resolve allegations of violations to the False Claims Act through fraudulent drug

pricing and marketing."

2004: Bristol-Myers Squibb was ordered by the Securities and Exchange Commission to

pay $150 million to settle charges of inflating its revenue by $1.5 billion in 2000

and 2001. A separate criminal investigation by the U.S. Attorney General's Office

in NJ resulted in the indictment of two executives for securities fraud -- the

company agreed to pay $300 million to shareholders.

2000: Wyeth signed an FDA Consent Decree and paid $30 million for failing to comply

with Good Manufacturing Practice.

1997: after pulling Pondimin and Redux off the market because of heart valve

damage, Wyeth was forced to set aside $21.1 billion to settle "fen-phen" liability

cases.

2005: Serono Laboratories (Switzerland) agreed to pay $704 million to resolve

criminal and civil charges in connection with the marketing of Serostim, an AIDS

drug. The company also pled guilty to marketing conspiracy.

2005: Eli Lilly pled guilty and paid $36 million for its illegal marketing of

Evista for off-label uses.